Truist lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $230 and keeps a Buy rating on the shares. The company’s inline total revenue was carried by robust momentum in oxybate franchise, off-set by softness in Epidiolex and oncology businesses, the analyst tells investors in a research note. Truist adds however that it is tempering its outlook for oxybate franchise as multiple non-oxybate alternatives to narcolepsy are on the horizon with two NDAs on deck in coming months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals: Strong Buy Rating Backed by Robust Growth and Promising Pipeline
- Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition
- 3 “Strong Buy” Growth Stocks to Buy Now, 8/5/2025, According to Analysts
- Jazz narrows FY25 EPS view $4.80-$5.60 from $4.00-$5.60
- Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)